TY - JOUR
T1 - Effective treatment of experimental ES-2 human ovarian cancers with a cytotoxic analog of luteinizing hormone-releasing hormone AN-207
AU - Arencibia, Jose M.
AU - Bajo, Ana M.
AU - Schally, Andrew V.
AU - Krupa, Magdalena
AU - Chatzistamou, Ioulia
AU - Nagy, Attila
PY - 2002/10/1
Y1 - 2002/10/1
N2 - The receptors for luteinizing hormone-releasing hormone (LHRH) are found in 80% of human ovarian carcinomas. These receptors can be used for targeted chemotherapy with cytotoxic analogs of LHRH, such as AN-207, consisting of 2-pyrrolinodoxorubicin (AN-201) linked to [D-Lys6]LHRH. We investigated the effects of AN-207 and AN-201 on the in vivo growth of LHRH receptor-positive ES-2 human ovarian cancers. The effects of the treatment on mRNA and protein levels of human epidermal growth factor (EGF) receptors (EGFR and HER-2) in ovarian tumors were determined by RT-PCR and immunoblotting. In Experiment 1, nude mice bearing ES-2 ovarian tumors were injected i.v. with 250 nmol/kg doses of AN-207, AN-201, the carrier [D-Lys6]LHRH, an unconjugated mixture of AN-201 and [D-Lys6]LHRH or vehicle. AN-207 caused a significant (p<0.01) 59.5% inhibition in tumor growth while its components were ineffective. In Experiment 2, mice with large ES-2 tumors were treated with AN-207 or AN-201 at 250 nmol/kg. Again, AN-207, but not AN-201, inhibited tumor growth. In Experiment 3, the site of action of AN-207 was investigated. The blockade of LHRH receptors with Cetrorelix partially suppressed the antitumor effect of AN-207. Treatment with AN-207 significantly (p<0.01) decreased the expression of mRNA for EGFR, and HER-2 by 27 and 34%, respectively, as compared to controls and reduced the receptor protein levels of EGFR and HER-2 by 35 and 36%, respectively (p<0.05).The results indicate that cytotoxic LHRH analog AN-207 could be considered for chemotherapy of ovarian cancers expressing LHRH receptors.
AB - The receptors for luteinizing hormone-releasing hormone (LHRH) are found in 80% of human ovarian carcinomas. These receptors can be used for targeted chemotherapy with cytotoxic analogs of LHRH, such as AN-207, consisting of 2-pyrrolinodoxorubicin (AN-201) linked to [D-Lys6]LHRH. We investigated the effects of AN-207 and AN-201 on the in vivo growth of LHRH receptor-positive ES-2 human ovarian cancers. The effects of the treatment on mRNA and protein levels of human epidermal growth factor (EGF) receptors (EGFR and HER-2) in ovarian tumors were determined by RT-PCR and immunoblotting. In Experiment 1, nude mice bearing ES-2 ovarian tumors were injected i.v. with 250 nmol/kg doses of AN-207, AN-201, the carrier [D-Lys6]LHRH, an unconjugated mixture of AN-201 and [D-Lys6]LHRH or vehicle. AN-207 caused a significant (p<0.01) 59.5% inhibition in tumor growth while its components were ineffective. In Experiment 2, mice with large ES-2 tumors were treated with AN-207 or AN-201 at 250 nmol/kg. Again, AN-207, but not AN-201, inhibited tumor growth. In Experiment 3, the site of action of AN-207 was investigated. The blockade of LHRH receptors with Cetrorelix partially suppressed the antitumor effect of AN-207. Treatment with AN-207 significantly (p<0.01) decreased the expression of mRNA for EGFR, and HER-2 by 27 and 34%, respectively, as compared to controls and reduced the receptor protein levels of EGFR and HER-2 by 35 and 36%, respectively (p<0.05).The results indicate that cytotoxic LHRH analog AN-207 could be considered for chemotherapy of ovarian cancers expressing LHRH receptors.
KW - Cytotoxic luteinizing hormone-releasing hormone analog
KW - Ovarian cancer
KW - Targeted chemotherapy
UR - http://www.scopus.com/inward/record.url?scp=0036812811&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036812811&partnerID=8YFLogxK
U2 - 10.1097/00001813-200210000-00007
DO - 10.1097/00001813-200210000-00007
M3 - Article
C2 - 12394258
AN - SCOPUS:0036812811
VL - 13
SP - 949
EP - 956
JO - Anti-Cancer Drugs
JF - Anti-Cancer Drugs
SN - 0959-4973
IS - 9
ER -